updated 10/5/2010 6:16:20 PM ET 2010-10-05T22:16:20

PHILADELPHIA, Oct. 5, 2010 (GLOBE NEWSWIRE) -- Spector Roseman Kodroff & Willis, P.C. ("SRKW") announces that class action lawsuits have been brought on behalf of purchasers of the securities of Arena Pharmaceuticals, Inc. ("Arena" or the "Company") (Nasdaq:ARNA) between December 8, 2008 and September 16, 2010, inclusive ("Class Period").

If you purchased Arena securities during the Class Period, you may move the Court for appointment as lead plaintiff by no later than November 19, 2010. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. Your share of any subsequent recovery in this action will not be affected by your decision whether to seek appointment as lead plaintiff.

The actions, pending in the United States District Court for the Southern District of California, were brought against Arena and certain of its officers for violations of federal securities laws. Arena, headquartered in San Diego, California, is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing oral drugs that target G protein-coupled receptors.  Arena's principal drug under development is Lorcaserin, an experimental weight loss drug.

The complaints allege that throughout the Class Period, defendants made materially false statements regarding Lorcaserin. Specifically, defendants allegedly touted Lorcaserin's purported efficacy, safety, and tolerability but failed to disclose certain health risks associated with the drug. On September 14, 2010, the Food and Drug Administration ("FDA") issued a briefing document in advance of its advisory panel meeting that questioned the safety and efficacy of Lorcaserin and revealed, among other things, that the drug was associated with malignant tumors in rats.  On this news, the price of Arena common stock fell $2.72 per share, or nearly 40 percent, to close at $4.13 per share on September 14, 2010. On September 16, 2010, the FDA advisory panel reportedly rejected Lorcaserin due to concerns with the drug's efficacy and potential safety problems.  The following day, September 17, 2010, Arena's stock fell another $1.75 per share, or approximately 47 percent, to close at $1.99 per share.

If you want to consider serving as a lead plaintiff and you bought Arena securities between December 8, 2008 and September 16, 2010, or wish to discuss this matter further, you are encouraged to contact the following SRKW attorneys via telephone or e-mail: 

About SRKW

SRKW has been representing individual and institutional investors for nearly three decades, serving as lead counsel in numerous securities class actions in U.S. federal and state courts. Please visit the firm's website ( http://www.srkw-law.com ) for more information about the firm.

The Spector Roseman Kodroff & Willis, P.C. logo is available at

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 3.79%
$30K home equity loan FICO 4.99%
$75K home equity loan FICO 4.69%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.83%
Cash Back Cards 17.80%
Rewards Cards 17.18%
Source: Bankrate.com